Zobrazeno 1 - 10
of 893
pro vyhledávání: '"Iain B. McInnes"'
Autor:
Iain B. McInnes, Philip J. Mease, Yoshiya Tanaka, Laure Gossec, M. Elaine Husni, Lars Erik Kristensen, Richard B. Warren, Barbara Ink, Rajan Bajracharya, Jason Coarse, Alice B. Gottlieb
Publikováno v:
ACR Open Rheumatology, Vol 6, Iss 11, Pp 720-731 (2024)
Objective The objective of this study was to assess 52‐week efficacy and safety of bimekizumab in patients with active psoriatic arthritis (PsA) with or without concomitant methotrexate (+/−MTX) treatment at baseline. Methods We conducted a post
Externí odkaz:
https://doaj.org/article/9bc82b35361540eca261704dc88423d0
Autor:
Sabha Asghar, Gary J. Litherland, John J. Cole, Iain B. McInnes, R. M. D. Meek, John C. Lockhart, Carl S. Goodyear, Anne Crilly
Publikováno v:
Arthritis Research & Therapy, Vol 26, Iss 1, Pp 1-14 (2024)
Abstract Background Small extracellular vesicles (sEV) derived from synovial fibroblasts (SF) represent a novel molecular mechanism regulating cartilage erosion in osteoarthritis (OA). However, a comprehensive evaluation using disease relevant cells
Externí odkaz:
https://doaj.org/article/3b5cf59e34534e7c8772f11be34ab22f
Autor:
Philip J. Mease, Joseph F. Merola, Yoshiya Tanaka, Laure Gossec, Iain B. McInnes, Christopher T. Ritchlin, Robert B. M. Landewé, Akihiko Asahina, Barbara Ink, Andrea Heinrichs, Rajan Bajracharya, Vishvesh Shende, Jason Coarse, Laura C. Coates
Publikováno v:
Rheumatology and Therapy, Vol 11, Iss 5, Pp 1363-1382 (2024)
Abstract Introduction Psoriatic arthritis (PsA) is a chronic inflammatory disease requiring long-term treatment. Bimekizumab, a monoclonal IgG1 antibody that selectively inhibits interleukin (IL)-17F in addition to IL-17A, has demonstrated tolerabili
Externí odkaz:
https://doaj.org/article/4bbb5fc59b154e17b4cb6d05b6603d8e
Autor:
Philip J. Mease, Richard B. Warren, Peter Nash, Jean-Marie Grouin, Nikos Lyris, Vanessa Taieb, Jason Eells, Iain B. McInnes
Publikováno v:
Rheumatology and Therapy, Vol 11, Iss 5, Pp 1413-1423 (2024)
Abstract Introduction A matching-adjusted indirect comparison (MAIC) was conducted to assess the relative efficacy at 52 weeks (Wk52) of bimekizumab 160 mg every 4 weeks (Q4W) and ustekinumab 45 or 90 mg every 12 weeks (Q12W) in patients with psoriat
Externí odkaz:
https://doaj.org/article/4262254099cb40d39645fcfe05396997
Autor:
Philip J. Mease, Richard B. Warren, Peter Nash, Jean-Marie Grouin, Nikos Lyris, Damon Willems, Vanessa Taieb, Jason Eells, Iain B. McInnes
Publikováno v:
Rheumatology and Therapy, Vol 11, Iss 5, Pp 1403-1412 (2024)
Abstract Introduction The relative efficacy of bimekizumab and risankizumab in patients with PsA who were biologic disease-modifying anti-rheumatic drug naïve (bDMARD naïve) or with previous inadequate response or intolerance to tumor necrosis fact
Externí odkaz:
https://doaj.org/article/ce35de981e1147979941d6203e2e5191
Autor:
Philip J. Mease, Richard B. Warren, Peter Nash, Jean-Marie Grouin, Nikos Lyris, Damon Willems, Vanessa Taieb, Jason Eells, Iain B. McInnes
Publikováno v:
Rheumatology and Therapy, Vol 11, Iss 3, Pp 817-828 (2024)
Abstract Introduction Matching-adjusted indirect comparisons (MAICs) were used to compare the efficacy of bimekizumab and secukinumab 150 mg and 300 mg at 52 weeks for the treatment of psoriatic arthritis (PsA) in patients who were biologic disease-m
Externí odkaz:
https://doaj.org/article/f5c52a1be9d64789923ca497a0e9b3a0
Autor:
Richard B. Warren, Iain B. McInnes, Peter Nash, Jean-Marie Grouin, Nikos Lyris, Damon Willems, Vanessa Taieb, Jason Eells, Philip J. Mease
Publikováno v:
Rheumatology and Therapy, Vol 11, Iss 3, Pp 829-839 (2024)
Abstract Introduction Matching-adjusted indirect comparisons (MAIC) were used to assess the relative efficacy of bimekizumab 160 mg every 4 weeks (Q4W) compared to guselkumab 100 mg Q4W or every 8 weeks (Q8W) at 48/52 weeks in patients with psoriatic
Externí odkaz:
https://doaj.org/article/160b6ba0575d44a484ca18255390de4e
Autor:
Jeffrey R. Curtis, Iain B. McInnes, Proton Rahman, Dafna D. Gladman, Steven Peterson, Feifei Yang, Oluwakayode Adejoro, Alexa P. Kollmeier, Natalie J. Shiff, Chenglong Han, May Shawi, William Tillett, Philip J. Mease
Publikováno v:
Rheumatology and Therapy, Vol 11, Iss 2, Pp 425-441 (2024)
Abstract Introduction To evaluate the effect of guselkumab on work productivity and nonwork daily activity impairment and general health status through 2 years in patients who were biologic-naïve with active psoriatic arthritis (PsA) in the phase 3
Externí odkaz:
https://doaj.org/article/0fe4fa79267340eca6264c7603694203
Autor:
Laura C. Coates, Proton Rahman, Philip J. Mease, May Shawi, Emmanouil Rampakakis, Alexa P. Kollmeier, Xie L. Xu, Soumya D. Chakravarty, Iain B. McInnes, Lai-Shan Tam
Publikováno v:
BMC Rheumatology, Vol 8, Iss 1, Pp 1-11 (2024)
Abstract Background To explore the trajectory of, and factors contributing to, achievement of individual criteria of minimal disease activity (MDA) in patients with active psoriatic arthritis (PsA) treated with guselkumab. Methods The Phase 3, random
Externí odkaz:
https://doaj.org/article/194d9d5826a142a58b96c1820ee7de94
Autor:
Christina Charles-Schoeman, Jon T. Giles, Nancy E. Lane, Ernest Choy, Daniel E. Furst, Jiří Vencovský, Anthony G. Wilson, Gerd R. Burmester, Derek Coombs, Sara K. Penn, Nasser Khan, Jillian B. Yee, Kassim Rahawi, Iain B. McInnes
Publikováno v:
Rheumatology and Therapy, Vol 11, Iss 1, Pp 157-175 (2024)
Abstract Introduction Upadacitinib (UPA) is a Janus kinase inhibitor that has demonstrated efficacy in moderate-to-severe rheumatoid arthritis (RA) with an acceptable safety profile. We investigated laboratory parameter changes in UPA RA clinical tri
Externí odkaz:
https://doaj.org/article/7848bcb7d51248bd8d20a0519b6de718